| A liposomal formulation of amikacin, administered once daily via inhalation following nebulization |
| Designed to facilitate targeted and localized drug delivery to the lungs while minimizing systemic exposure |
| As an add-on to guidelines-based therapy (GBT), ALIS significantly increases the odds of achieving sputum culture conversion compared with GBT alone |
| Acceptable tolerability; carries a black box warning pertaining to a risk of increased respiratory adverse events (leading to hospitalizations in some cases) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.